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stop thinking about your problems?” The item “how much have you looked 
forward to things with enjoyment?” was changed to “how much of the time did 
you feel enjoyment?”, and “how much have you felt useful?” was revised to read 
“how much of the time did you feel useful?” CONCLUSIONS: When 
translatability assessment is conducted prior to the finalization of a new 
measure, language changes can be implemented that will facilitate translation 
and cross cultural adaptation. When difficulties are encountered that may not 
warrant changes on their own, results from translatability assessments can also 
be useful in adding awareness and greater weight to other aspects of item 
structure that might need to be altered to improve the integrity and quality of 
the measure.  
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OBJECTIVES: Patients with schizophrenia frequently switch between 
antipsychotics, underscoring the need to ensure that important treatment 
outcomes such as health-related quality of life (HRQL) are achieved and 
maintained following the switch. This analysis evaluated changes in overall 
health-related quality of life among patients with schizophrenia switched from 
current antipsychotic treatment to lurasidone. METHODS: Stable, but 
symptomatic outpatients with schizophrenia were switched from their current 
antipsychotic to lurasidone, in a 6-week, open-label trial, conducted in the US. 
The Personal Evaluation of Transitions in Treatment (PETiT) is a validated 30-
item instrument measuring self-reported overall quality of life outcomes among 
patients with schizophrenia. In addition, PETiT assesses two domain scores on 
psychosocial functioning and adherence related attitude. Higher scores on PETiT 
denote better HRQL. PETiT scale was administered at baseline and study 
endpoint. Changes from baseline to study endpoint in PETiT total score (overall 
HRQL) and domain scores (psychosocial functioning and adherence) were 
compared using ANCOVA with baseline score, treatment, and pooled site as 
covariates. RESULTS: Of the 244 patients switched to lurasidone from other 
antipsychotics, patients with available data on PETiT (n=213) were included in 
the analysis. Mean PETiT total scores at baseline was 35.3 and at study endpoint 
was 38.5. Mean change from baseline to the study endpoint in the PETiT total 
score was 3.2, change in psychosocial functioning domain score was 2.5, and 
change in adherence domain score was 0.7, significant in all patient groups 
(p<0.001). CONCLUSIONS: The findings from this study indicate that patients 
switching from other antipsychotics to lurasidone experienced statistically 
significant improvement in HRQL, psychosocial functioning and adherence 
related attitude within six weeks of treatment. Further investigation regarding 
the effects of longer-term lurasidone treatment on HRQL outcomes is warranted.  
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OBJECTIVES: Caregiver burden and social support play a crucial role in 
moderating the treatment outcomes of children with autism. It is important for 
health care services researchers to consider the impact of these constructs while 
understanding treatment outcomes. The goal of this study is to provide a 
comprehensive review of instruments that have been used to measure caregiver 
burden and social support in autism. METHODS: A systematic literature review 
was conducted from January 2002 - December 2012 using the databases: Medline, 
PsychINFO, Cochrane, Mental measurements year book and Health and 
psychosocial instruments to identify instruments. The psychometric properties 
of the instruments have been assessed. Inclusion / exclusion criteria that were 
applied to the study are: language, availability of full text articles, and relevance 
to the topic of study. RESULTS: The review also yielded 20 instruments for 
measuring social support. Of these, 19 were generic and 1 was condition-specific. 
The most common domains included in the instruments were: instrumental 
support and emotional support. Some instruments consisted of domains based 
on source of social support such as informal support from friends, family and 
spouse. A review of the psychometric properties of these instruments indicated 
good reliability (Cronbach’s alpha 0.7 – 0.95). Caregiver burden has been studied 
less frequently as compared to social support. Caregiver burden was mostly 
measured using 4 instruments. Of these four instruments, Caregiver Strain 
Questionnaire has been validated in a population of parents of autistic children. 
It has good reliability (Cronbach’s alpha 0.75 – 0.93) CONCLUSIONS: Caregiver 
burden and social support are two important constructs that affect the quality of 
life (QoL) of caregivers of children with autistic disorder. Consideration of the 
nature and extent of caregiver burden and social support will also facilitate the 
development of appropriate interventions that can help improve caregivers’ 
quality of life (QoL) and functioning.  
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OBJECTIVES: This study investigates impairments and propensities for risky 
behaviors among adults diagnosed with attention-deficit/hyperactivity disorder 
(ADHD) in Europe (E) and the United States (US). METHODS: Data are from a web-
based survey of adults who self-report having an ADHD diagnosis. Data were 
gathered October-December 2012 in Germany, UK, Netherlands, Sweden and the 
U.S. Participants were asked questions regarding social, family, educational and 
work-related impairments and risky personal behaviors previously shown to be 
common among adults with ADHD. Chi-square tests of proportions were used to 
test for significant differences between European and U.S. participants reported 
below. RESULTS: Three hundred European and 100 US adults reporting a 
diagnosis of ADHD from a health care professional completed the survey online. 
60% of both European and US respondents agreed that ADHD has had a negative 
impact on their career success. Over one-in-four respondents reported a 
suspension some time during school (31% E vs. 23% US; p<0.05). Twenty-six 
percent of European respondents reported 3 or more traffic tickets within the 
past year (vs. 9% US; p<.05); 11% reported 3 or more automobile accidents during 
the same period (vs. 9% US). Eighteen percent of Europeans also reported having 
had more than three job-related accidents or injuries requiring medical attention 
during this period (vs. 2 % US; p<0.05). Over 40% of study participants reported 
illegal drug use at some time in the past (44% E vs. 48% US), with around 10% 
reporting citations for driving under the influence of alcohol or drugs (15% E vs. 9 
% US) or serving time in prison (11% each). Concern about exposure to a sexually 
transmitted disease was reported by 34% European and 44% US (p<0.05) study 
participants. CONCLUSIONS: ADHD Adults from Europe and the US report 
various impairments and risky behaviors possibly related to their condition, 
some more frequent among European than US participants.  
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OBJECTIVES: The impact of MDD on HRQOL is well documented, but little 
information exists about commonly used HRQoL instruments’ adherence to EMA 
requirements for psychometric properties and content relevance. This work 
examines commonly used HRoQL instruments for their relevance to MDD, based 
on their content, concepts measured and psychometric properties, and use in 
published MDD studies. METHODS: A qualitative research paper provided a 
conceptual model for MDD (1). The SF-36 Health Survey (SF-36), Sheehan 
Disability Scale (SDS), Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q), Health Status Questionnaire-12 (HSQ-12) and EuroQol (EQ-5D) were 
mapped to this conceptual model to examine their relevance to MDD. The 
measures’ reliability, validity, responsiveness to change in depression and use in 
MDD trials and labelling were examined through review of classic databases 
(including: PROQOLID, PROLABEL, MEDLINE, PSYCHINFO, FDA, EMA). Where no 
information on MDD was available, data for mood disorders were explored. 
RESULTS: The SF-36, SDS, Q-LES-Q and EQ-5D have been widely used in MDD, 
with SDS and Q-LES-Q results included as part of approved EMA labelling claims 
in mood disorder indications. These instruments are clinically well established 
and the combination covers HRQoL concepts relevant to the MDD population 
[emotional/social/physical (specifically bodily pain)]; Q-LES-Q and SF-36 are the 
most comprehensive HRQoL measures. All instruments met EMA psychometric 
requirements for validity, reliability and responsiveness to changes in depressive 
symptoms and in elderly populations for the HSQ-12. Furthermore, the 
instruments have been linguistically validated for use in many countries. 
CONCLUSIONS: These commonly used instruments are relevant to MDD and 
meet EMA criteria for reliability, validity and responsiveness. Thus, we conclude 
that these instruments are appropriate for use in clinical programmes to assess 
the impact of MDD treatment on HRQoL and overall functioning, particularly to 
support claims in Europe.  
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OBJECTIVES: To build a conceptual model describing disease experience in 
adolescent ADHD (aged 13–17) and impact of treatment, in order to inform the 
development of a measurement strategy to evaluate interventions. Conceptual 
models that summarize key concepts in describing disease experience are useful 
for developing strategies to measure meaningful treatment outcomes. 
Adolescents are increasingly participating in making decisions about their health 
care. Hence, it is important to evaluate outcomes that are meaningful to them. 
METHODS: In preparation for patient interviews, focused searches of databases, 
clinical and regulatory guidelines, ADHD specific tools and conference abstracts 
were conducted as part of the literature review to identify concepts to 
understand the experiences of adolescents with ADHD from various 
perspectives. In addition, concept elicitation interviews with 10 clinicians, 3 
teachers, 10 peers and 10 siblings of adolescents with ADHD were conducted 
using semi-structured guides. Results from this preliminary stage were analyzed 
systematically; transcripts from the peer and sibling interviews were analyzed 
using a pre-defined coding dictionary, to identify concepts for the model. 
RESULTS: Disease-defining concepts in ADHD included core ADHD symptoms, 
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problems with cognitive functions and problems with emotional dysregulation. 
ADHD was seen to impact everyday activities, social interactions and emotional 
functioning. These impacts had implications for the achievements at school; 
self-esteem and indulgence in risky behavior. Variables that moderate these 
impacts were also identified. The interrelationships among variables will be 
presented. The model was used to inform a strategy to evaluate outcomes of 
pharmacological treatments in adolescents with ADHD. The plausibility of the 
model was confirmed based on discussions with clinicians and drug 
development experts. CONCLUSIONS: An ADHD disease conceptual model was 
developed based on information from literature and stakeholders interviews, to 
describe ADHD in adolescents. It will be used to develop a strategy for PRO 
development in adolescent ADHD and identify new outcomes.  
 
PMH54  
ADHD AMONG ADULTS IN EUROPE AND THE UNITED STATES: SOCIO-
DEMOGRAPHICS, COMORBIDITIES, HEALTH CARE RESOURCE USE AND WORK 
PRODUCTIVITY  
Able SL1, Haynes V1, Vietri J2, Kopenhafer L3, Upadhyaya H1, Deberdt W4 
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kantar Health, Princeton, NJ, USA, 3Kantar 
Health, New York, NY, USA, 4S.A. Eli Lilly Benelux N.V., Bruxelles, Belgium  
OBJECTIVES: To compare socio-demographic characteristics, comorbidities, 
health care resource use and work productivity assessments among adults 
diagnosed with attention-deficit/hyperactivity disorder (ADHD) from Europe (E) 
and the United States (US). METHODS: Data are from the 2011 National Health 
and Wellness Survey (NHWS), conducted online annually by Kantar Health 
among samples of adults obtained from international consumer panels. Data 
reported in this study were gathered September-December 2011 in Germany, UK, 
France, Spain, Italy, and the U.S. Comparisons of ADHD and non-ADHD control 
populations were presented previously. Those results are extended below, by 
comparing to differences between European and U.S. study participants, using 
chi-square tests of proportions. RESULTS: A total of 235 European and 676 US 
NHWS participants reported having received a diagnosis for ADHD from a health 
care professional. Diagnosed ADHD respondents were more frequently male 
(59% E vs. 56% US) and less likely married (38% E vs. 33% US) than non-ADHD 
controls. ADHD respondents were more likely to report sleep difficulties (67% E 
vs. 44% US; p<.05), anxiety (61% E vs. 58% US), depression (59% E vs. 60% US), or 
headaches (57% E vs. 63% US) than non-ADHD controls. Likelihoods of an 
emergency room visit (34% E vs. 24% US; p<0.05), or a hospitalization (32% E vs. 
12% US; p<0.05) within the past 6 months were greater among diagnosed ADHD 
respondents than non-ADHD controls. Diagnosed ADHD respondents were also 
more likely to report health-related work productivity loss (55% E vs. 34% US; 
p<0.05). CONCLUSIONS: Adults from Europe and the US reported high rates of 
comorbidity with various mental, emotional, or physical disorders, high rates of 
health resource utilization, and high rates of health-related work productivity 
loss, with many of these higher among European than US participants.  
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OBJECTIVES: Depression has a significant detrimental effect on HRQoL and 
functioning. The aim of this study was to assess HRQoL outcomes in randomized 
placebo-controlled studies of adult MDD patients receiving vortioxetine. 
METHODS: Effects on HRQoL and functioning were evaluated in adult MDD 
patients using the Short-Form 36 (SF-36), the Quality of Life Enjoyment and 
Satisfaction Scale-Short Form (Q-LES-Q-SF), the EuroQoL Five-Dimension (EQ-
5D), the Health Status Questionnaire (HSQ-12) and the Sheehan Disability Scale 
(SDS). Furthermore, HRQoL and functioning were assessed in a short-term study 
in elderly MDD patients (≥65 years). A random effects meta-analysis was 
performed on the short-term vortioxetine studies (n=4 for SF-36 and n=7 for 
SDS). Values are presented as change from baseline versus placebo. RESULTS: 
Adult patients were treated with placebo (n=1316) or vortioxetine (n=2155). The 
meta-analysis (FAS, MMRM) showed a statistically significant difference to 
placebo in favour of vortioxetine in the SF-36 Mental Component Summary 
(MCS) score (5mg: 2.6, p=0.001, n=604; 20mg: 4.8, p<0.001, n=328) and 4 domain 
scores (vitality, social functioning, role-emotional, and mental health). 
Standardised effect sizes showed the clinical relevance of these results. 
Improvement was significantly different from placebo in the EQ-5D Health State 
score for vortioxetine 10mg (7.5 points, p<0.05, n=86) (FAS, MMRM) and the Q-
LES-Q total score for vortioxetine 15mg (3.3 points, p<0.01, n=127) and 20mg (4.5 
points, p<0.0001, n=134) (FAS, LOCF). Improvement in functioning, measured 
with the SDS, was in favour of vortioxetine 10mg (-1.7, p=0.004, n=269) and 20mg 
(-2.4, p=0.006, n=234) (FAS, MMRM). In the elderly study, improvement in the 
HSQ-12 for vortioxetine 5mg (n=136) was significantly different from placebo 
(n=128) for Health Perception (10.4, p<0.0001), Mental Health (7.9, p<0.001), and 
Energy (6.4, p<0.05) domains (FAS, MMRM). CONCLUSIONS: Vortioxetine showed 
significant and meaningful improvements in HRQoL and functioning versus 
placebo across several MDD trials and relevant outcome instruments.  
 
PMH56  
GLOBAL TREATMENT SATISFACTION: PRESENTATION OF A LATENT VARIABLE 
APPROXIMATING MODEL  
Ciesla J1, Mazurek K2, Yao P1 
1Northern Illinois University, DeKalb, IL, USA, 2Uinversity of Illinois Urbana Champaign, Urbana, 
IL, USA  
OBJECTIVES: This research presents an approximating model of global 
treatment satisfaction (GS) created using econometric techniques. GS questions 
are usually worded, “All things considered, how satisfied are you with the care 
you received…?” The economic interpretation of GS is higher satisfaction 
corresponds to higher utility. When thought of as utility, GS is tied to the 
assumptions of utility maximizing imbedded in consumer theory, and more 
specifically, to the concept of demand. Attempts in the literature to measure GS 
fall short because of lack of theoretical guidance and inconsistency in 
measurement and variable operationalization. We avoid these limitations by 
presenting a methodological approach that makes it possible to view GS from an 
economic perspective. METHODS: The model is based on data from an outcomes 
study of substance abuse treatment services; however, it can be used for any 
treatment population. The participants are 311 adults (average age 36.4) 
discharged from primary treatment (ASAM Level 1A) in 2006-2010. The model is 
based on a single ordinal five-item GS variable and two treatment-relevant 
covariates: post-treatment time abstinent from use (treatment outcome), and an 
adjustor variable indicating addiction severity. GS is treated as a latent variable. 
It is specified using ordered probit regression under the log-linear functional 
form. The structural part of the relation is isolated by setting the model error 
term to zero. RESULTS: The model estimate for the outcome variable is 0.205 
(S.E. 0.041; X2<0.0001), and for the severity variable 0.722 (S.E. 0.431; χ2 N.S). A set 
of GS indifference curves are presented based on severity and outcome 
equivalencies. CONCLUSIONS: The effort necessary to obtain higher GS 
increases on the margin. This is important given the strong relationship between 
addiction severity and treatment cost and given treatment resource constraints. 
This technique can be incorporated into the quality assurance activities in any 
health care setting.  
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OBJECTIVES: Prescribing of more than one antidepressant drug (poly-pharmacy) 
is not clinically substantiated in literature and such a practice could contribute 
to additional side-effects. Antidepressant drugs are prescribed to patients 
diagnosed with psychiatric and non-psychiatric medical conditions. The 
objective of this study was to determine the patient demographics, non-
demographic factors and physician characteristics associated with prescribing 
poly-pharmacy antidepressants in both psychiatric and non-psychiatric cases. 
METHODS: The 2000-2009 National Ambulatory Medical Care Survey database 
was accessed for medical records of patients who were prescribed the 
antidepressant drugs. The medical records were sorted into psychiatric and non-
psychiatric categories. A logistic regression analysis helped determine the 
patient demographic, non-demographic and physician characteristics associated 
with prescribing poly-pharmacy antidepressant drugs. RESULTS: For patients 
diagnosed with psychiatric illnesses: Patient demographic factors of age 
(p<0.0001), gender (p=0.0087), race/ethnicity (p=0.0091), method of payment 
(p=0.0283), non-demographic factors of diagnosis (p<0.0001), and number of 
medical condition diagnosed (p<0.0001, OR=1.259, CI=1.125-1.408) were 
significantly associated with prescribing poly-pharmacy antidepressant drugs. 
Among the physician related factors, physician specialty (p<0.0001) and the 
region of practice (South) (p=0.0475) were significantly associated with 
prescribing poly-pharmacy antidepressant drugs. For patients diagnosed with 
non-psychiatric illnesses: Patients’ age (p<0.0001), method of payment 
(p=0.0444), and among the non-demographic characteristics, the number of 
medical conditions diagnosed (p=0.0246, OR=1.16, CI=1.019-1.320), and patients 
diagnosed with circulatory system disease (p=0.0111) were significantly 
associated with the practice of poly-pharmacy. Of the physician related factors 
physicians classified as owners of non-solo practice (p=0.0306) were significantly 
associated with prescribing poly-pharmacy antidepressant drugs. 
CONCLUSIONS: The fact that more than 40% of poly-pharmacy antidepressant 
drugs was prescribed to patients diagnosed with non-psychiatric illnesses, and 
the significant association between the poly-pharmacy antidepressants 
prescribed and the number of medical conditions diagnosed in both psychiatric 
and non-psychiatric patients lends to further investigation as to the 
reasonableness of such practices.  
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OBJECTIVES: Several medicines are available in the Brazilian public health 
system (SUS) to treat schizophrenia. The Ministry of Health (MoH) and Brazilian 
states share the responsibility of acquiring the atypical antipsychotics, which 
have significant impact on the public budget. Here, we present the profile of 
financial resources allocated in the acquisition of atypical antipsychotics in the 
SUS. METHODS: Descriptive analysis of expenses with drugs, based on the 
amount dispensed and acquisition prices in 2011. Data were obtained from MoH 
databases. For quetiapine, olanzapine, risperidone and ziprasidone, we assumed 
the financial resources applied by both states and MoH; for clozapine, we needed 
to accounted only the MoH resources (current values of 2011; exchange rate: 
US$1 = R$2.04). RESULTS: In 2011, expenses with atypical antipsychotics 
(clozapine, quetiapine, olanzapine, risperidone, and ziprasidone) for 
